Literature DB >> 19531343

Preliminary analysis of influenza A(H1N1)v individual and aggregated case reports from EU and EFTA countries.

.   

Abstract

Since the first importation of influenza A(H1N1)v virus to Europe in late April of this year, surveillance data have been collected in the Member States of the European Union and European Free Trade Association. This is the first preliminary analysis of aggregated and individual data available as of 8 June 2009 at European level.

Entities:  

Mesh：

Year:  2009        PMID： 19531343     DOI： 10.2807/ese.14.23.19238-en

Source DB:  PubMed          Journal:  Euro Surveill        ISSN： 1025-496X


  14 in total

1.  Epidemiological aspects of pandemic influenza A(H1N1) virus from 2009 to 2011 in Iran.

Authors:  Jila Yavarian; Maryam Naseri; Azadeh Shadab; Nazanin Z Shafiei Jandaghi; Talat Mokhtari Azad
Journal:  Influenza Other Respir Viruses       Date:  2012-04-06       Impact factor: 4.380

2.  Adaptive vaccination strategies to mitigate pandemic influenza: Mexico as a case study.

Authors:  Gerardo Chowell; Cécile Viboud; Xiaohong Wang; Stefano M Bertozzi; Mark A Miller
Journal:  PLoS One       Date:  2009-12-03       Impact factor: 3.240

3.  2009 Pandemic influenza A virus subtype H1N1 in Morocco, 2009-2010: epidemiology, transmissibility, and factors associated with fatal cases.

Authors:  Amal Barakat; Hassan Ihazmad; Fatima El Falaki; Stefano Tempia; Imad Cherkaoui; Rajae El Aouad
Journal:  J Infect Dis       Date:  2012-12-15       Impact factor: 5.226

4.  Using sentinel surveillance system to monitor seasonal and novel H1N1 influenza infection in Houston, Texas: outcome analysis of 2008-2009 flu season.

Authors:  Salma Khuwaja; Osaro Mgbere; Adebowale Awosika-Olumo; Fayaz Momin; Katherine Ngo
Journal:  J Community Health       Date:  2011-10

5.  Comparison of the Roche RealTime ready Influenza A/H1N1 Detection Set with CDC A/H1N1pdm09 RT-PCR on samples from three hospitals in Ho Chi Minh City, Vietnam.

Authors:  Nguyen thi Tham; Vu thi Ty Hang; Trong Huu Khanh; Do Chau Viet; Tran Tinh Hien; Jeremy Farrar; Nguyen van Vinh Chau; H Rogier van Doorn
Journal:  Diagn Microbiol Infect Dis       Date:  2012-07-09       Impact factor: 2.803

6.  Onset of a pandemic: characterizing the initial phase of the swine flu (H1N1) epidemic in Israel.

Authors:  Uri Roll; Rami Yaari; Guy Katriel; Oren Barnea; Lewi Stone; Ella Mendelson; Michal Mandelboim; Amit Huppert
Journal:  BMC Infect Dis       Date:  2011-04-14       Impact factor: 3.090

Review 7.  Guidelines on management of human infection with the novel virus influenza A (H1N1)--a report from the Hospital das Clínicas of the University of São Paulo.

Authors:  Ludhmila Abrahao Hajjar; Denise Schout; Filomena Regina Barbosa Gomes Galas; David Everson Uip; Anna Sara Shafferman Levin; Helio Hehl Caiaffa Filho; Pedro Takanori Sakane; Carlos Alberto Suslik; Jose Manoel de Camargo Teixeira; Eloisa Bonfa; Antonio Alci Barone; Milton de Arruda Martins; Marcos Boulos; Jose Otavio Costa Auler
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 8.  Epidemiology of human infection with the novel virus influenza A (H1N1) in the Hospital das Clínicas, São Paulo, Brazil--June-September 2009.

Authors:  Denise Schout; Ludhmila Abrahao Hajjar; Filomena Regina Barbosa Gomes Galas; David Everson Uip; Anna Sara Shafferman Levin; Helio Hehl Caiaffa Filho; Pedro Takanori Sakane; Carlos Alberto Suslik; Jose Manoel de Camargo Teixeira; Eloisa Bonfa; Antonio Alci Barone; Milton de Arruda Martins; Marcos Boulos; Jose Otavio Costa Auler
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

9.  The novel influenza A (H1N1) virus pandemic: An update.

Authors:  N Petrosillo; S Di Bella; C M Drapeau; E Grilli
Journal:  Ann Thorac Med       Date:  2009-10       Impact factor: 2.219

10.  Epidemiological characteristics of novel influenza A (H1N1) in antiviral drug users in Korea.

Authors:  Kyunghi Choi; Sung-il Cho; Masahiro Hashizume; Ho Kim
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.